AstraZeneca Pharm. LP. v. Teva Pharm. USA, Inc., No. 08-1480

By FindLaw Staff on September 25, 2009 | Last updated on March 21, 2019

In a patent case involving claims for the antipsychotic drug quetiapine, district court's grant of limited motion for summary judgment of no inequitable conduct in favor of plaintiffs-AstraZeneca, is affirmed as defendants had not presented evidence sufficient for a reasonable jury to find that in the prosecution of the patent application, plaintiff made a misrepresentation of material fact or an omission of material fact, with intent to deceive or mislead the patent examiner into granting the patent.     

Read AstraZeneca Pharm. LP. v. Teva Pharm. USA, Inc., No. 08-1480

Appellate Information

Appeal from:  United States District Court for the District of New Jersey

Decided September 25, 2009

Judges

Before Newman, Rader, and Prost, Circuit Judges

Opinion by Newman, Circuit Judge.   

Counsel

For Appellant:  Henry J. Renk, Fitzpatrick Cella, Harper & Scinto

For Appellee:  Ira J. Levy, Goodwin Procter LLP

Copied to clipboard